Cargando…

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS

Efficacy of therapeutic dendritic cell vaccines (DCV) can be limited by immunosuppressive mechanisms in the micromilieu of high-grade gliomas. In the HIT-HGG-Rez Immunovac trial (Eudra-CT 2013-000419-26), we investigate whether a reduction of Treg with metronomic cyclophosphamide (metrCyc) might be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eyrich, Matthias, Krauss, Jürgen, Rachor, Johannes, Monoranu, Camelia, Bison, Brigitte, Löhr, Mario, Rückriegel, Stefan, Wölfl, Matthias, Miller, Elisabeth, Schlegel, Paul G, Kramm, Christof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715918/ http://dx.doi.org/10.1093/neuonc/noaa222.366

Ejemplares similares

IMMU-07. Interim analysis of the HIT-HGG Rez Immunvac study - Dendritic cell vaccination with partial T(reg) depletion and double checkpoint blockade in children with relapsed high-grade gliomas.
por: Eyrich, Matthias, et al.
Publicado: (2022)

MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register
por: Tschirner, Sebastian, et al.
Publicado: (2022)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

IMMU-06. Landscape of adaptive immunity of childhood brain cancers
por: Raphael, Itay, et al.
Publicado: (2022)

IMMU-02. Targeted innovative antibody fragment-based immunotherapy for medulloblastoma
por: Niesen, Judith, et al.
Publicado: (2022)

IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

IMMU-20. Effective CAR-T cell medulloblastoma therapy in an immunocompetent mouse model
por: Tsahouridis, Rania, et al.
Publicado: (2022)

IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors
por: Levine, Adrian, et al.
Publicado: (2022)

HGG-16. Final analysis of the HIT-HGG-2007 trial (ISRCTN19852453): Significant survival benefit for pontine and non-pontine pediatric high-grade gliomas in comparison to previous HIT-GBM-C/-D trials.
por: von Bueren, Andrè O, et al.
Publicado: (2022)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies
por: Adolph, Jonas E., et al.
Publicado: (2021)

Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
por: Ottensmeier, Holger, et al.
Publicado: (2020)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020)

IMMU-28. IMMUNOGENOMIC ANALYSIS REVEALS LGALS1 CONTRIBUTES TO THE IMMUNE HETEROGENEITY AND IMMUNOSUPPRESSION IN GLIOMA
por: Chen, Qun, et al.
Publicado: (2020)

IMMU-10. TUMOR ASSOCIATED MYELOID CELLS DRIVE THE IMMUNOBIOLOGY OF HIGH RISK PEDIATRIC EPENDYMOMA
por: Griesinger, Andrea, et al.
Publicado: (2022)

IMMU-05. Integrative transcriptomic analysis of pilocytic astrocytomas reveals CNS region-associated characteristics
por: Rozowsky, Jacob S, et al.
Publicado: (2022)

IMMU-18. Targeting Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas
por: Labiano, Sara, et al.
Publicado: (2022)

Dendritic Cell Vaccination in Pediatric Gliomas: Lessons Learnt and Future Perspectives
por: Eyrich, Matthias, et al.
Publicado: (2013)

IMMU-21. INVESTIGATION OF WHITE BLOOD CELL CHARACTERISTICS IN CSF SAMPLES AT PEDIATRIC BRAIN TUMOR DIAGNOSIS
por: Greer, Hunter, et al.
Publicado: (2020)

IMMU-11. LOCOREGIONAL DELIVERY OF TRANSIENT GD2 CAR T CELLS FOR SAFE AND EFFECTIVE TREATMENT OF DIPG
por: Foster, Jessica, et al.
Publicado: (2020)

IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors
por: Nabbi, Arash, et al.
Publicado: (2022)

IMMU-23. Novel gene-edited CAR-T cell therapy against Diffuse Intrinsic Pontine Glioma
por: Balakrishnan, Ilango, et al.
Publicado: (2022)

IMMU-07. “STROKE MIMICS” ARE NOT BENIGN IN IMMUNOCOMPROMISED CHILDREN
por: Mahdi, Jasia, et al.
Publicado: (2021)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-16. INTRA-TUMOURAL IL-12 DELIVERY ENABLES CAR T-CELL IMMUNOTHERAPY FOR HIGH-GRADE GLIOMA
por: Agliardi, Giulia, et al.
Publicado: (2020)

IMMU-22. Safely targeting GD2 in thalamic diffuse midline glioma with mRNA CAR T cells
por: Foster, Jessica, et al.
Publicado: (2022)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-03. CHARACTERIZING THE IMMUNE MICROENVIRONMENT OF PEDIATRIC BRAIN TUMORS
por: Galvin, Robert, et al.
Publicado: (2021)

Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study
por: Gaab, Christine, et al.
Publicado: (2022)

IMMU-13. CUSTOMIZABLE MULTI-LAMELLAR RNA-NANOPARTICLES FOR PEDIATRIC GLIOMA
por: Mendez-Gomez, Hector, et al.
Publicado: (2021)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

IMMU-07. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE
por: Brown, Brandon, et al.
Publicado: (2020)

IMMU-30. UPREGULATED T CELL AND INTERFERON-Γ-RELATED GENE EXPRESSION IS ASSOCIATED WITH INCREASED SURVIVAL IN RECURRENT PEDIATRIC HIGH-GRADE GLIOMA
por: Davidson, Tom, et al.
Publicado: (2020)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY
por: Bouffet, Eric, et al.
Publicado: (2020)

IMMU-15. QUANTIFYING INTRATHECAL DRUG DELIVERY UTILIZING PROGRAMMABLE VENTRICULOPERITONEAL SHUNTS
por: McThenia, Sheila, et al.
Publicado: (2021)

IMMU-12. PHASE I/II TRIAL OF IMMUNOTHERAPY WITH FUSIONS OF DENDRITIC CELLS AND TUMOR CELLS FOR RELAPSED OR REFRACTORY BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS
por: Yamaoka, Masayoshi, et al.
Publicado: (2020)

IMMU-14. SynNotch chimeric antigen receptor (CAR) T-cells as a potential treatment for diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG)
por: Ferrerosa, Lauren, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k96p44f7mvgghcr04ofjo6slql